The effect of Curcumin on Osteoporosis in Post Menopausal Women

Effects of Curcumin on Bone Turnover markers and Bone Densitometry characteristics in Post Menopausal Women with Osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016030424308N1

Enrollment

Registered

2016-12-04

Start date

2016-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis. Postmenopausal osteoporosis

Interventions

Intervention 1: Control group : No intervention. Intervention 2: Alendronate groups: Alendronate is administered at a dose of 5 mg/kg of body weight per day for 12 months . Intervention 3: Alendro

Treatment - Drugs

Control group : No intervention

Alendronate groups: Alendronate is administered at a dose of 5 mg/kg of body weight per day for 12 months .

Alendronate + curcumin group: alendronate at a dose of 5 mg/kg of body weight per day for 12 months + curcumin at a dose of 110 mg/kg of body weight per day for 12 months

Curcumin group: curcumin at a dose of 110 mg/kg of body weight per day for 12 months

Eligibility

Sex/Gender

Female

Age

55 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 55- 65 years, At least 5 years after the last menstrual period and Osteoporosis. Exclusion criteria: any secondary cause of osteoporosis such as metabolic or endocrine disease, affecting bone drugs such as Bisphosphonates, Calcium and Vitamin D, Cardiovascular, Cereberovascular, Rheumatologic disease, Alcohol and or smoking

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bone-specific alkaline phosphatase. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Osteocalcin. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Type 1 of Telopeptides. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Femoral Neck Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Total Hip Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Lumbar Spine Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.	—

Measure

Time frame

Bone-specific alkaline phosphatase. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Osteocalcin. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Type 1 of Telopeptides. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Femoral Neck Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Total Hip Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.;Lumbar Spine Bone Mineral Density. Timepoint: Baseline and after 12 months. Method of measurement: laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Hafezi Ahmadi

Ilam University of Medical Sciences

reza.ahmadi56@gmail.com+98 84 2333 2132

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026